ATE366584T1 - Verwendung von glp-1 peptiden - Google Patents

Verwendung von glp-1 peptiden

Info

Publication number: ATE366584T1
Authority: AT; Austria
Prior art keywords: glp; peptides; satiety; appetite; analogue
Prior art date: 1996-11-12

Application number

AT05002085T

Other languages

English (en)

Inventor

Liselotte Bjerre Knudsen

Lars Thim

Martin Edward Judge

Jens Juul Holst

Arne Vernon Astrup

Brigitte Schellerup Wulff

Original Assignee

Novo Nordisk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-11-12

Filing date

1997-11-07

Publication date

2007-08-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8102971&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE366584(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-11-07 Application filed by Novo Nordisk As filed Critical Novo Nordisk As

2007-08-15 Application granted granted Critical

2007-08-15 Publication of ATE366584T1 publication Critical patent/ATE366584T1/de

Links

102400000322 Glucagon-like peptide 1 Human genes 0.000 title 1
102100025101 GATA-type zinc finger protein 1 Human genes 0.000 abstract 1
101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 1
235000019789 appetite Nutrition 0.000 abstract 1
230000036528 appetite Effects 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
239000012634 fragment Substances 0.000 abstract 1
230000006698 induction Effects 0.000 abstract 1
230000002093 peripheral effect Effects 0.000 abstract 1
230000036186 satiety Effects 0.000 abstract 1
235000019627 satiety Nutrition 0.000 abstract 1
230000001629 suppression Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Obesity (AREA)
Gastroenterology & Hepatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Zoology (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Child & Adolescent Psychology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

AT05002085T 1996-11-12 1997-11-07 Verwendung von glp-1 peptiden ATE366584T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DK127096		1996-11-12

Publications (1)

Publication Number	Publication Date
ATE366584T1 true ATE366584T1 (de)	2007-08-15

Family

ID=8102971

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT97911155T ATE289517T1 (de)	1996-11-12	1997-11-07	Verwendung von glp-1 peptiden
AT05002085T ATE366584T1 (de)	1996-11-12	1997-11-07	Verwendung von glp-1 peptiden

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT97911155T ATE289517T1 (de)	1996-11-12	1997-11-07	Verwendung von glp-1 peptiden

Country Status (9)

Country	Link
US (5)	US20030232754A1 (de)
EP (2)	EP0941114B1 (de)
JP (1)	JP2001504105A (de)
AT (2)	ATE289517T1 (de)
AU (1)	AU4863797A (de)
DE (2)	DE69737916T2 (de)
ES (2)	ES2290799T3 (de)
WO (1)	WO1998020895A1 (de)
ZA (1)	ZA9710182B (de)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6852690B1 (en)	1995-08-22	2005-02-08	Amylin Pharmaceuticals, Inc.	Method and composition for enhanced parenteral nutrition
UA65549C2 (uk)	1996-11-05	2004-04-15	Елі Ліллі Енд Компані	Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US6380357B2 (en)	1997-12-16	2002-04-30	Eli Lilly And Company	Glucagon-like peptide-1 crystals
US6998387B1 (en)	1998-03-19	2006-02-14	Amylin Pharmaceuticals, Inc.	Human appetite control by glucagon-like peptide receptor binding compounds
US7223727B2 (en)	1998-04-09	2007-05-29	Serono Genetics Institute S.A.	GSSP4 polynucleotides and polypeptides and uses thereof
US6720407B1 (en) *	1998-08-28	2004-04-13	Eli Lilly And Company	Method for administering insulinotropic peptides
US6927214B1 (en)	1999-01-15	2005-08-09	Novo Nordisk A/S	Non-peptide GLP-1 agonists
US6514500B1 (en) *	1999-10-15	2003-02-04	Conjuchem, Inc.	Long lasting synthetic glucagon like peptide {GLP-!}
ATE545652T1 (de)	1999-06-29	2012-03-15	Mannkind Corp	Reinigung und stabilisierung von proteinen und peptiden in pharmaceutischen agentien
US9006175B2 (en)	1999-06-29	2015-04-14	Mannkind Corporation	Potentiation of glucose elimination
ATE381343T1 (de) *	1999-11-03	2008-01-15	Novo Nordisk As	Verwendung eines wachstumshormons oder eines wachstumshormon-sekretion fördernden mittels zur appetit-unterdrückung bzw. sättigungsinduktion
EP1983055A1 (de)	2000-04-12	2008-10-22	Human Genome Sciences, Inc.	Albuminfusionsproteine
AU2001256757B2 (en) *	2000-05-16	2006-03-09	Sanwa Kagaku Kenkyusho Co., Ltd.	Agents for preventing or ameliorating insulin resistance and/or obesity
DE60228408D1 (de) *	2001-02-09	2008-10-02	Serono Genetics Inst Sa	Gssp4-polynukleotide und -polypeptide sowie deren verwendung
NZ532427A (en)	2001-09-24	2008-07-31	Imp Innovations Ltd	Modification of feeding behavior using PYY (peptide YY) and its agonists such as NPY (neuropeptide Y)
AU2002364587A1 (en)	2001-12-21	2003-07-30	Human Genome Sciences, Inc.	Albumin fusion proteins
PT1463751E (pt)	2001-12-21	2013-08-26	Human Genome Sciences Inc	Proteínas de fusão de albumina
EP1478233B1 (de)	2002-02-20	2016-11-09	Emisphere Technologies, Inc.	Verfahren zur verabreichung von glp1- molekülen
ATE385193T1 (de)	2002-03-20	2008-02-15	Mannkind Corp	Inhalationsgerät
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
EP1594530A4 (de)	2003-01-22	2006-10-11	Human Genome Sciences Inc	Albuminfusionsproteine
DE602004031455D1 (de)	2003-12-09	2011-03-31	Novo Nordisk As	Regulierung der nahrungspräferenz mit glp-1-agonisten
US20060286129A1 (en)	2003-12-19	2006-12-21	Emisphere Technologies, Inc.	Oral GLP-1 formulations
DK1729795T3 (en)	2004-02-09	2016-04-11	Human Genome Sciences Inc	Albumin fusion proteins
CN1956998B (zh)	2004-04-23	2012-12-12	康久有限责任公司	用于纯化白蛋白结合物的方法
CN1950078A (zh) *	2004-06-11	2007-04-18	诺和诺德公司	使用glp－1激动剂抵抗药物诱发的肥胖
CA2575692C (en)	2004-08-20	2014-10-14	Mannkind Corporation	Catalysis of diketopiperazine synthesis
KR20150039211A (ko)	2004-08-23	2015-04-09	맨카인드 코포레이션	약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
EA012287B1 (ru)	2005-06-30	2009-08-28	Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентифик С.А.С.	Фармацевтическая композиция glp-1
WO2007033372A2 (en)	2005-09-14	2007-03-22	Mannkind Corporation	Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
DE602005017628D1 (de)	2005-09-22	2009-12-24	Biocompatibles Uk Ltd	Fusionspolypeptide vom glp-1 (glucagon-like peptide-1) mit erhöhten peptidaseresistenz
US8039432B2 (en)	2005-11-09	2011-10-18	Conjuchem, Llc	Method of treatment of diabetes and/or obesity with reduced nausea side effect
US8293869B2 (en)	2005-12-16	2012-10-23	Nektar Therapeutics	Polymer conjugates of GLP-1
MX360812B (es)	2006-02-22	2018-11-16	Mannkind Corp	Un método para mejorar las propiedades farmacéuticas de micropartículas que contienen dicetopiperazina y un agente activo.
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
SG174054A1 (en)	2006-05-04	2011-09-29	Boehringer Ingelheim Int	Polymorphs
EP1852108A1 (de)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	Zusammensetzungen von DPP-IV-Inhibitoren
EP1854455B1 (de)	2006-05-10	2009-10-07	Biocompatibles UK Limited	GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung
WO2008012629A2 (en)	2006-07-24	2008-01-31	Biorexis Pharmaceutical Corporation	Exendin fusion proteins
TWI428346B (zh)	2006-12-13	2014-03-01	Imp Innovations Ltd	新穎化合物及其等對進食行為影響
EP2190873B1 (de) *	2007-09-05	2015-07-22	Novo Nordisk A/S	Verkürzte glp-1-derivate und ihre therapeutische verwendung
US8895694B2 (en)	2007-09-05	2014-11-25	Novo Nordisk A/S	Glucagon-Like Peptide-1 derivatives and their pharmaceutical use
BRPI0818874A2 (pt) *	2007-10-24	2015-05-05	Mannkind Corp	Liberação de agentes ativos
AU2008316634B2 (en) *	2007-10-24	2014-02-27	Mannkind Corporation	Method of preventing adverse effects by GLP-1
US8785396B2 (en)	2007-10-24	2014-07-22	Mannkind Corporation	Method and composition for treating migraines
PE20140960A1 (es)	2008-04-03	2014-08-15	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
US8485180B2 (en)	2008-06-13	2013-07-16	Mannkind Corporation	Dry powder drug delivery system
MX395141B (es)	2008-06-13	2025-03-24	Mannkind Corp	Inhalador de polvo y sistema para suministro de farmaco.
CA2728523C (en)	2008-06-20	2020-03-10	Mannkind Corporation	An interactive apparatus and method for real-time profiling of inhalation efforts
KR20190016601A (ko)	2008-08-06	2019-02-18	베링거 인겔하임 인터내셔날 게엠베하	메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
TWI532497B (zh)	2008-08-11	2016-05-11	曼凱公司	超快起作用胰島素之用途
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US8314106B2 (en)	2008-12-29	2012-11-20	Mannkind Corporation	Substituted diketopiperazine analogs for use as drug delivery agents
EP2216042A1 (de)	2009-02-09	2010-08-11	Ipsen Pharma S.A.S.	GLP1-analoge pharmazeutische Zusammensetzungen
CA2754595C (en)	2009-03-11	2017-06-27	Mannkind Corporation	Apparatus, system and method for measuring resistance of an inhaler
TWI547487B (zh)	2009-06-12	2016-09-01	曼凱公司	具限定比表面積之二酮基哌微粒子
US20120148586A1 (en)	2009-08-27	2012-06-14	Joyce Ching Tsu Chou	Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
JP5784622B2 (ja)	2009-11-03	2015-09-24	マンカインドコーポレ−ション	吸入活動をシミュレートするための装置及び方法
EA034869B1 (ru)	2009-11-27	2020-03-31	Бёрингер Ингельхайм Интернациональ Гмбх	Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
MX341025B (es)	2010-05-05	2016-08-04	Boehringer Ingelheim Int Gmbh *	Terapia de combinacion.
RU2571331C1 (ru)	2010-06-21	2015-12-20	Маннкайнд Корпорейшн	Системы и способы доставки сухих порошковых лекарств
RU2013103763A (ru)	2010-07-02	2014-08-10	Ангиохем Инк.	Короткие и содержащие d-аминокислоты полипептиды для терапевтических конъюгатов и их применения
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
MX345501B (es)	2010-12-16	2017-02-02	Novo Nordisk As	Composiciones solidas que comprenden agonista de glp-1 y sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico.
RU2569776C2 (ru)	2011-04-01	2015-11-27	Маннкайнд Корпорейшн	Блистерная упаковка для фармацевтических картриджей
DK2696687T3 (en)	2011-04-12	2017-02-06	Novo Nordisk As	Double-acylated GLP-1 derivatives
WO2012174472A1 (en)	2011-06-17	2012-12-20	Mannkind Corporation	High capacity diketopiperazine microparticles
AU2012328885B2 (en)	2011-10-24	2017-08-31	Mannkind Corporation	Methods and compositions for treating pain
US20130172244A1 (en) *	2011-12-29	2013-07-04	Thomas Klein	Subcutaneous therapeutic use of dpp-4 inhibitor
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
TR201903918T4 (tr)	2012-03-22	2019-04-22	Novo Nordisk As	Bir dağıtım ajanı içeren bileşimler ve bunların hazırlanması.
RS57727B1 (sr)	2012-03-22	2018-12-31	Novo Nordisk As	Kompozicije glp-1 peptida i njihovo dobijanje
US20130303462A1 (en)	2012-05-14	2013-11-14	Boehringer Ingelheim International Gmbh	Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
JP6218811B2 (ja)	2012-05-14	2017-10-25	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6517690B2 (ja)	2012-06-20	2019-05-22	ノヴォノルディスクアー／エス	ペプチド及び送達剤を含む錠剤製剤
BR112015000529B1 (pt)	2012-07-12	2022-01-11	Mannkind Corporation	Inalador de pó seco
WO2014066856A1 (en)	2012-10-26	2014-05-01	Mannkind Corporation	Inhalable influenza vaccine compositions and methods
ES2928365T3 (es)	2013-03-15	2022-11-17	Mannkind Corp	Composiciones de dicetopiperazina microcristalina, métodos de preparación y uso del mismo
ES2688462T3 (es)	2013-05-02	2018-11-02	Novo Nordisk A/S	Dosificación oral de compuestos de GLP-1
AU2014272500B2 (en)	2013-05-28	2018-03-08	Scohia Pharma, Inc.	Peptide compound
MX375448B (es)	2013-07-18	2025-03-06	Mannkind Corp	Composiciones farmacéuticas en polvo seco estables al calor y métodos.
JP2016530930A (ja)	2013-08-05	2016-10-06	マンカインドコーポレイション	通気装置及び方法
JP6615109B2 (ja)	2014-02-28	2019-12-04	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｄｐｐ−４阻害薬の医学的使用
US10307464B2 (en)	2014-03-28	2019-06-04	Mannkind Corporation	Use of ultrarapid acting insulin
US10561806B2 (en)	2014-10-02	2020-02-18	Mannkind Corporation	Mouthpiece cover for an inhaler
JP6995042B2 (ja)	2016-05-24	2022-02-04	武田薬品工業株式会社	ペプチド化合物
BR112018072401A2 (pt)	2016-06-10	2019-02-19	Boehringer Ingelheim International Gmbh	combinações de linagliptina e metformina
CN118873634A (zh)	2018-02-02	2024-11-01	诺和诺德股份有限公司	包含glp-1激动剂、n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐和润滑剂的固体组合物
CN113181346A (zh) *	2018-03-09	2021-07-30	上海仁会生物制药股份有限公司	用于治疗肥胖和体重管理的glp-1组合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5120712A (en) *	1986-05-05	1992-06-09	The General Hospital Corporation	Insulinotropic hormone
US5118666A (en) *	1986-05-05	1992-06-02	The General Hospital Corporation	Insulinotropic hormone
US5418218A (en) *	1992-07-10	1995-05-23	The University Of Maryland At Baltimore	Histidyl-proline diketopiperazine (cyclo his-pro) a cns-active pharmacologic agent
US5380872A (en) *	1992-07-14	1995-01-10	Glaxo Inc.	Modulators of cholecystokinin
US5912229A (en) *	1996-03-01	1999-06-15	Novo Nordisk Als	Use of a pharmaceutical composition comprising an appetite-suppressing peptide
UA70283C2 (en) *	1996-03-01	2004-10-15	Novo Nordisk As	Peptide (variants), a pharmaceutical composition cpeptide (variants), a pharmaceutical composition composed of peptide and a method for the preparatioomposed of peptide and a method for the preparation thereof (variants) n thereof (variants)
US6458924B2 (en) *	1996-08-30	2002-10-01	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US7235627B2 (en) *	1996-08-30	2007-06-26	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US6268343B1 (en) *	1996-08-30	2001-07-31	Novo Nordisk A/S	Derivatives of GLP-1 analogs
UA65549C2 (uk) *	1996-11-05	2004-04-15	Елі Ліллі Енд Компані	Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
EP1629849B2 (de) *	1997-01-07	2017-10-04	Amylin Pharmaceuticals, LLC	Pharmazeutische Zusammensetzungen enthaltend Exendine und deren Agonisten
HU222513B1 (hu) *	1998-01-30	2003-08-28	Novo Nordisk A/S	Injekciós fecskendő
US6420137B1 (en) *	1998-11-25	2002-07-16	American Home Products Corporation	Nucleic acid encoding human neurotensin subtype 2 receptor
US6528486B1 (en) *	1999-07-12	2003-03-04	Zealand Pharma A/S	Peptide agonists of GLP-1 activity
US6399089B1 (en) *	2000-05-15	2002-06-04	A. Glenn Braswell	Compositions and methods for regulating metabolism and balancing body weight
US20020187926A1 (en) *	2001-03-07	2002-12-12	Knudsen Liselotte Bjerre	Combined use of derivatives of GLP-1 analogs and PPAR ligands
US7041646B2 (en) *	2001-10-05	2006-05-09	Bayer Pharmaceuticals Corporation	Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists

1997
- 1997-11-07 ES ES05002085T patent/ES2290799T3/es not_active Expired - Lifetime
- 1997-11-07 AT AT97911155T patent/ATE289517T1/de not_active IP Right Cessation
- 1997-11-07 AT AT05002085T patent/ATE366584T1/de not_active IP Right Cessation
- 1997-11-07 AU AU48637/97A patent/AU4863797A/en not_active Abandoned
- 1997-11-07 DE DE69737916T patent/DE69737916T2/de not_active Revoked
- 1997-11-07 EP EP97911155A patent/EP0941114B1/de not_active Expired - Lifetime
- 1997-11-07 WO PCT/DK1997/000509 patent/WO1998020895A1/en active IP Right Grant
- 1997-11-07 JP JP52206198A patent/JP2001504105A/ja not_active Ceased
- 1997-11-07 ES ES97911155T patent/ES2237790T3/es not_active Expired - Lifetime
- 1997-11-07 DE DE69732572T patent/DE69732572T2/de not_active Expired - Lifetime
- 1997-11-07 EP EP05002085A patent/EP1529534B1/de not_active Revoked
- 1997-11-12 ZA ZA9710182A patent/ZA9710182B/xx unknown
2003
- 2003-03-06 US US10/382,438 patent/US20030232754A1/en not_active Abandoned
2007
- 2007-03-05 US US11/714,000 patent/US20070161568A1/en not_active Abandoned
2009
- 2009-02-12 US US12/370,308 patent/US20090149387A1/en not_active Abandoned
2010
- 2010-01-04 US US12/651,685 patent/US20100113363A1/en not_active Abandoned
- 2010-10-15 US US12/905,324 patent/US20110028391A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20030232754A1 (en)	2003-12-18
ES2290799T3 (es)	2008-02-16
US20100113363A1 (en)	2010-05-06
DE69737916D1 (de)	2007-08-23
EP0941114B1 (de)	2005-02-23
US20070161568A1 (en)	2007-07-12
EP1529534A2 (de)	2005-05-11
AU4863797A (en)	1998-06-03
EP0941114A1 (de)	1999-09-15
US20110028391A1 (en)	2011-02-03
EP1529534B1 (de)	2007-07-11
WO1998020895A1 (en)	1998-05-22
ZA9710182B (en)	1998-05-12
ATE289517T1 (de)	2005-03-15
JP2001504105A (ja)	2001-03-27
DE69737916T2 (de)	2008-04-03
DE69732572T2 (de)	2005-12-29
EP1529534A3 (de)	2005-06-08
DE69732572D1 (de)	2005-03-31
US20090149387A1 (en)	2009-06-11
ES2237790T3 (es)	2005-08-01

Publication	Publication Date	Title
DE69732572D1 (de)	2005-03-31	Verwendung von glp-1 peptiden
NO940219L (no)	1994-03-25	Rekombinante antistoffer for human terapi
ATE306931T1 (de)	2005-11-15	Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
AU8402691A (en)	1992-03-17	Dental curing lamp and apparatus
NO961796L (no)	1996-11-06	Rekombinante fedme (ob) proteiner
BG100974A (en)	1998-04-30	Vaccines against papillomavirus
GB0123381D0 (en)	2001-11-21	Factor
GB9418775D0 (en)	1994-11-02	Vaccine for the preventoin of porcine reproductive and respiratory syndrome
AU1255383A (en)	1983-09-29	Foot and mouth disease viral antigenic peptides
EE04741B1 (et)	2006-12-15	Sigade sigimis- ja hingamissündroomi vaktsiin
ZA941426B (en)	1994-10-04	Recombinant viruses and their use in gene therapy
DE69528531D1 (de)	2002-11-14	D-2-alkyltryptophan enthaltende polypeptide mit wachstumhormon freisetzender aktivitaet
GB9101191D0 (en)	1991-02-27	Wound treatment
FI952372A7 (fi)	1995-11-19	Menetelmä luonnollisella N-terminaalisella sekvenssillä varustettujen yhdistelmäaprotiniinin ja yhdistelmäaprotiniinvarianttien valmistamise ksi
AU2623088A (en)	1989-11-03	New anti-receptor peptides and therapeutic agents
DK522582A (da)	1983-05-26	Peptider, deres fremstilling og anvendelse
MX9205978A (es)	1993-04-01	Nuevas proteinas inhibidoras de trombina de garrapatas.
EE03187B1 (et)	1999-06-15	Pakett hormoonasendusraviks
ZA925615B (en)	1993-04-28	Recombinant antibodies for human therapy
NZ333652A (en)	2000-07-28	Inhibition of human rotavirus infection using kappa-casein
AU1649592A (en)	1992-12-21	Recombinant immunocastration vaccine and polypeptides useful for same
SE9100284D0 (sv)	1991-01-30	Novel peptide
GB9013872D0 (en)	1990-08-15	Use of protein a and polypeptide components thereof in the treatment of tumours
IT230068Y1 (it)	1999-04-30	Maschera-filtro per anestesia e rianimazione.
NO924293D0 (no)	1992-11-06	Cykliserte og lineaere terapeutiske peptider

Legal Events

Date	Code	Title	Description
2008-01-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties